Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 8/20 | 0.37 |
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32665181 | 0.78 | KDM4E (0.47) | MGLLFAAHALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL32665530 | 0.76 | MGLL (0.47) | MGLLFAAHGSK3AGSK3BALDH1A1 | |
| SCHEMBL32665464 | 0.73 | MGLL (0.47) | MGLLFAAHGSK3AGSK3BHSP90AA1 | |
| SCHEMBL32665162 | 0.69 | PTGS1 (0.54) | MGLLFAAHGSK3AGSK3BALDH1A1 | |
| SCHEMBL32665550 | 0.68 | MGLL (0.60) | MGLLFAAHGSK3AGSK3B | |
| SCHEMBL32665528 | 0.67 | GSK3A (0.51) | MGLLFAAHGSK3AGSK3BALDH1A1 | |
| SCHEMBL32665507 | 0.67 | MGLL (0.49) | MGLLFAAHGSK3AGSK3BALDH1A1 | |
| SCHEMBL17982847 | 0.66 | GAA (0.56) | ALDH1A1 | |
| SCHEMBL32665443 | 0.64 | MC4R (0.37) | ALDH1A1LMNA | |
| SCHEMBL12068775 | 0.64 | KMT2A (0.51) | FAAHALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | SOS1 1564/4885HTR6 4206/4885MGLL 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.